Responding to a recent request for input from the field, the AHA yesterday urged the Center for Medicare and Medicaid Innovation to balance the risk and reward in its alternative payment models “in a way that reflects the significant investments required to launch and maintain APM participation.” It also urged CMMI to “factor implementation periods into any future APMs and reduce mid-model changes to the greatest degree possible,” noting that many AHA members “have indicated they need one to two years to make all the necessary operational, administrative and clinical adjustments to succeed in models.” In addition, AHA urged CMMI to ensure participants “have timely, usable data about their attributed populations,” and “support providers’ ability to deliver accessible, equitable care to patients.” 

Related News Articles

Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The AHA May 1 expressed concerns to the Centers for Medicare & Medicaid Services about the payment process established under the Medicare Drug…
Headline
The Supreme Court April 29 ruled 7-2 in favor of the Department of Health and Human Services in a case that challenged how HHS applied Congress’ formula for…